Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
Janet B McGillRajiv AgarwalStefan D AnkerGeorge L BakrisGerasimos FilippatosBertram PittLuis M RuilopeAndreas L BirkenfeldMaria L CaramoriMeike BrinkerAmer JosephAndrea LageRobert LawatscheckCharlie ScottEllen Burgessnull nullPublished in: Diabetes, obesity & metabolism (2023)
Finerenone efficacy was not modified by baseline HbA1c, HbA1c variability, diabetes duration or baseline insulin use. Greater HbA1c variability appeared to be associated with an increased risk of cardiorenal outcomes.